Bangladesh Makes 16 Vaccines. A Certificate Is What Stands Between Them and the World.

Bangladesh has produced vaccines since 2011 and Incepta alone makes 16, including pneumonia, cervical cancer and rabies vaccines. WHO Maturity Level 3 certification is targeted for May 2027.

By the UISC BD Editorial Desk · United Information Service Center · Published 9 September 2026 · 6-minute read

Very few developing countries manufacture their own vaccines. Bangladesh is one of them — and has been since 2011.

Three companies — Incepta, Popular and Healthcare — produce between 15 and 16 types of human and animal vaccines domestically. Incepta Pharmaceuticals alone manufactures 16 vaccines, including those for pneumonia, cervical cancer and rabies.

That is a genuinely uncommon industrial capability. It is also, at present, almost entirely confined to the domestic market — and the reason is not technical.

The Bottleneck Is a Regulator, Not a Factory

To export vaccines to most highly regulated markets, a manufacturer needs WHO prequalification. To obtain WHO prequalification, the manufacturer's national drug regulator must itself hold Maturity Level 3 (ML-3) certification from the World Health Organization.

ML-3 signifies that a country's drug regulatory authority is robust, well managed and internationally recognised. Bangladesh's Directorate General of Drug Administration (DGDA) is currently at Maturity Level 2.

Without ML-3, the WHO does not accept prequalification applications from Bangladeshi vaccine manufacturers at all. The consequence is precise and frustrating: Incepta exports only small quantities to a few African countries, and the wider export market remains closed regardless of product quality.

The Target: May 2027

Following a formal WHO assessment mission in 2021, Bangladesh was given a target of satisfying 211 indicators to reach ML-3. The government is now working toward achieving that certification by May 2027, explicitly to unlock investment and export.

Manufacturers, for their part, need to invest in meeting WHO current Good Manufacturing Practice (cGMP) standards and strengthen technical capability.

It is worth being clear about what this means: the constraint is institutional capacity at the regulator, not the competence of the factories. Bangladesh already manufactures the overwhelming majority of the medicines it consumes and exports pharmaceuticals to more than 160 countries. The pharmaceutical industry is one of the country's genuine industrial successes.

What ML-3 Would Actually Unlock

The prize is substantial and specific.

Global vaccine supply is concentrated among a small number of producers, a vulnerability the world experienced directly during the COVID-19 pandemic when low-income countries waited at the back of the queue. Institutions including Gavi and the WHO have since pushed deliberately to diversify manufacturing into more countries.

Bangladesh is unusually well positioned to benefit from that push: it already has functioning vaccine plants, an established pharmaceutical export industry, and costs far below those of European or North American producers. What it lacks is the regulatory credential that lets buyers purchase from it.

The Asian Development Bank has published analysis specifically on vaccine manufacturing in Bangladesh, which is itself a signal of how seriously the opportunity is taken by development finance institutions.

A Realistic Assessment

May 2027 is a target, and regulatory maturity assessments have slipped in many countries before. Nearly a decade has already passed since Bangladesh began pursuing this, and 211 indicators is a demanding checklist for any regulator to satisfy.

But this is an unusually tractable problem. It requires institutional strengthening — staffing, systems, inspection capability and documentation — rather than new industrial capacity or scientific breakthrough. Those are things a determined government can build with money and administrative attention.

For investors in Bangladesh's pharmaceutical sector, ML-3 is the single date worth tracking. It is the moment a domestic industry becomes an export industry.

Related reading

• Bangladesh Makes 98% of Its Own Medicine — and Exports to 160 Countries
• Bangladesh's API Park: Making the Ingredients, Not Just the Pills
• An mRNA Cancer Vaccine Has Succeeded in a Late-Stage Trial for the First Time
• Bangladesh Set Out to Vaccinate 50 Million Children Against Typhoid

Sources

• "Bangladesh's vaccine export dreams on hold over WHO certification," The Business Standard — tbsnews.net
• "Govt aims to fulfil WHO vaccine industry requirements by May 2027 to boost investment, export," The Business Standard — tbsnews.net
• "Vaccine Manufacturing in Bangladesh," ADB Brief 300, Asian Development Bank — adb.org
• "Incepta Pharmaceuticals," Wikipedia — en.wikipedia.org